Protein therapeutics is artificially synthesized protein which is used in treatment of chronic diseases such as cancer, diabetes and CVD. It is manufactured on large scale through genetically modified host cells. Globally, development of novel and efficient drugs, rising incidences of chronic disorders such as cardiovascular, cancer, diabetes, and others, rise in the awareness among people regarding protein therapeutics, increasing focus on research and development process, growing number of medical insurance services, and advantages of protein based drugs such as, minimal side effects results in high acceptance levels are the prime growth drivers of protein therapeutics market. In addition, increase in adoption of protein therapeutics in emerging economies such as China, India and others, will create new opportunities for protein therapeutics market. However, higher cost of the research and development, and complex government approval processes are the key restraints for protein therapeutics market.
Geographically North America dominated protein therapeutics market, with approximately half of the market in the U.S. because of high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing incidences of chronic diseases, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing population in developing nations such as China, and India in this region. Among all the type, Monoclonal Antobodies (mAbs) segment has the highest market share in protein therapeutics market due to higher prevalence of cancer patients.
This report identifies the global protein therapeutics market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global protein therapeutics market.
This report segments protein therapeutics market on the basis of type, functionality and regional market as follows:
- Protein Therapeutics Market, By Type: Monoclonal Antobodies (mAbs), Erythropoietin (EPO), Insulin, Interferon (IFN), Human Growth Hormone (HGH), Follicle Stimulating Hormone (FSH), Blood Clotting Factors, and Others
- This report has been segmented by functionality of protein therapeutic such as: Group I: Enzymatic or Regulatory Activity, Group II: Special Targeting Activity, Group III: Protein Vaccines, and Group IV: Protein Diagnostics
- This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the protein therapeutics market. Some of the major companies’ profiles in detail are as follows:
- Eli Lilly & Company
- Abbott Laboratories
- Group Biogen Idec Inc.
- Merck Serono S.A.
- Amgen Inc.